Discover & Learn

Hugo Levillain, Anne Royer Moës, Cristiana Gameiro-Paris, Antero Abrunhosa, Tom Deakin, Geraldine Gebhart, Matthias M. Herth, Jean-François Gestin, Ferid Haddad, Andreas Ingemann Jensen, Rebecca Lo Bue, Renata Mikolajczak, Adrian Otamendi, Katie Staunton-Mann, Kevin Tabury & Patrick Flamen on behalf of the Accelerate.EU consortium

Targeted Alpha Therapy (TAT) holds considerable promise for precision oncology, yet its clinical deployment in Europe remains limited. Beyond scientific considerations, progress is constrained by fragmentation across the radiopharmaceutical value chain, encompassing radionuclide production, radiochemistry, preclinical validation, clinical development, regulatory frameworks, infrastructure, and workforce training. 

Simplified preparation. Better controlled dilution (critical step). Standard size vials. Efficient, fast and robust.

IBA intends to propose commercial kits for AlF-peptide process on Synthera^®+ (IFP, reagents, ancillaries).
Precursor and final formulation are to be purchased by the customer and will not be provided by IBA.

Radiolabeled analog of estradiol is used as a PET imaging probe for estrogen receptor-positive breast cancer lesions.

To ensure that the obtained product meets quality control requirements for drug release we decided to use high pressure liquid chromatography purification (HPLC).

Flotufolastat (previously known as ¹⁸F rhPSMA-7.3) developed by Blue Earth Diagnostics stands out as a promising theranostic radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) receptor. Diagnostic ¹⁸F-flotufolastat enables high-resolution PET imaging of PSMA-expressing lesions. Its favorable positron energy and longer half-life (109.8 minutes – comparing to ⁶⁸Ga-labeled compounds) enhance image quality and sensitivity.
Approved by the FDA for commercial use.
It can also be labeled with therapeutic radiometals (such as ¹⁷⁷Lu and ²²⁵Ac) for targeted radiotherapy. The dual-labeling capability opens avenues for targeted radiotherapy, potentially improving treatment outcomes.

The paper highlights the unique capabilities of the IBA Cyclone^® KIUBE, particularly its variable energy feature. The application of this feature was demonstrated through hundreds of routine production runs of the ⁶⁸Ga-liquid target with improved radionuclidic purity, longer shelf-life, and higher activity levels.

Mohammed Bhuiyan, Jeffrey Souris, Anna Kucharski, Richard Freifelder, Jogeshwar Mukherjee, Chin-Tu Chen